The Hidden Danger of IgAN: Pathogenesis and Unmet Needs
Jonathan Barratt, MD, PhD
Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN
Chee Kay Cheung, MBChB, MRCP, PhD
Jörg Latus, MD
The Future of IgAN Care
An De Vriese, MD, PhD
The Evolving Role of Biomarkers in IgAN
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Gianluigi Savarese, MD, PhD, FESC, FHFA
CKD-aP Uncovered Prevalence & Pathophysiology
Steven Fishbane, MD
Nancy Helou, PhD
Spotlight on Assessment: Tools That Capture CKD-aP
Federico Alberici, MD, PhD
Anastasia Liossatou, PhD, RN
From Scratch to Strategy: Talking About CKD-aP in Clinical Practice
When Itching Hurts: Quality of Life Disruption in CKD-aP
What You Don’t See: A Patient’s View of Living with CKD-aP
Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Sayna Norouzi, MD
Extra Innings – Sustaining Victory Beyond the First Game
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Turning the Double Play – Comprehensive Secondary Prevention
Small Ball Wins Games – Combination Therapy for Goal Attainment
Swing for the Fences – LDL-C as the Power Hitter
Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines
Brendon Neuen, MBBS, PhD